Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis

James J DiNicolantonio, James H O’Keefe, William Wilson

ABSTRACT
Because serum magnesium does not reflect intracellular magnesium, the latter making up more than 99% of total body magnesium, most cases of magnesium deficiency are undiagnosed. Furthermore, because of chronic diseases, medications, decreases in food crop magnesium contents, and the availability of refined and processed foods, the vast majority of people in modern societies are at risk for magnesium deficiency. Certain individuals will need to supplement with magnesium in order to prevent suboptimal magnesium deficiency, especially if trying to obtain an optimal magnesium status to prevent chronic disease. Subclinical magnesium deficiency increases the risk of numerous types of cardiovascular disease, costs nations around the world an incalculable amount of healthcare costs and suffering, and should be considered a public health crisis. That an easy, cost-effective strategy exists to prevent and treat subclinical magnesium deficiency should provide an urgent call to action.

MAGNESIUM IN HUMAN BIOLOGY
Magnesium is the fourth most common intracellular cation (potassium being the first). Extracellular magnesium accounts for only ~1% of total body magnesium, which is found primarily in serum and red blood cells.

Magnesium is the seventh most abundant element in the Earth’s crust by mass or molarity...In vertebrates, magnesium is extremely abundant and it is the second most common intracellular cation (potassium being the first). Extracellular magnesium accounts for only ~1% of total body magnesium, which is found primarily in serum and red blood cells.

Magnesium is the fourth most common cation in our body, the second most common intracellular cation and the most common intracellular divalent cation. The human body contains around 25 g of magnesium. Magnesium is necessary for the functioning of over 300 enzymes in human, with 90% of total body magnesium being contained in the muscles and bones (~27% and ~63%, respectively), 90% of which is bound and with only 10% being free. In the serum, 32% of magnesium is bound to albumin, whereas 55% is free.

Some of the main functions of magnesium in human biology include the maintenance of ionic gradients (keeping intracellular sodium and calcium low and potassium high), cellular and tissue integrity, mitochondrial oxidative phosphorylation (ATP production and activation), and DNA, RNA and protein synthesis and integrity.

The elimination of magnesium is mainly controlled by the kidneys, increasing in the urine when there is magnesium surplus and falling to just 1 μEq of magnesium (~12 mg) during deficits. However, despite renal conservation, magnesium can be pulled from the bone (as well as muscles and internal organs) in order to maintain normal serum magnesium levels when intakes are low. Thus, a normal serum magnesium level does not rule out magnesium deficiency, which predisposes to osteopaenia, osteoporosis and fractures.

An excess of heavy metals due to soil contamination and a lack of minerals due to soil erosion also may predispose to micronutrient deficits. The importance of the mineral content of soil and water, once greatly appreciated, think low iodine levels in soil and the increased prevalence of goitre, has all but been forgotten. Furthermore, refined foods are depleted of magnesium during their processing. In order to prevent chronic diseases, we need to change our mindset away from exclusively treating acute illness and instead focus more on treating the underlying causes of chronic diseases, such as magnesium deficiency.

There are two types of nutrient deficiencies, frank deficiencies (such as scurvy from ascorbic acid deficiency or goitre from iodine deficiency) and subclinical deficiencies (a clinically silent reduction in physiological, cellular and/or biochemical functions). It is the latter that is most concerning as it is hard to diagnose and predisposes to numerous chronic diseases. And while both result in negative health consequences, the former has obvious symptoms (hence frank deficiency), whereas the latter may have negative or variable health effects that are not so apparent (eg, vascular calcification). The evidence

1Department of Preventive Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, Missouri, USA
2Hospital Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA

Correspondence to
Dr James J DiNicolantonio; jjdicnico@gmail.com

To cite: DiNicolantonio JJ, O’Keefe JH, Wilson W. Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis. Open Heart 2018;5:e000668. doi:10.1136/openhrt-2017-000668

Received 2 June 2017
Revised 6 October 2017
Accepted 7 November 2017

Open Access

in the literature suggests that subclinical magnesium deficiency is rampant and one of the leading causes of chronic diseases including cardiovascular disease and early mortality around the globe, and should be considered a public health crisis.\textsuperscript{12-14}

MAGNESIUM INTAKE

‘The homeostatic mechanisms to regulate magnesium balance were developed millions of years ago. Investigations of the macro- and micro-nutrient supply in Paleolithic nutrition of the former hunter/gatherer societies showed a magnesium uptake with the usual diet of about 600 mg magnesium/day, much higher than today’. Our homeostatic mechanisms and genome are still the same as with our ancestors in the Stone Age. This means our metabolism is best adapted to a high magnesium intake.\textsuperscript{5}

In developed countries, the average intake of magnesium is slightly over 4 mg/kg/day.\textsuperscript{15} More than a quarter of obese and non-obese youth have inadequate intakes of magnesium (27% and 29%, respectively). The authors of a study concluded: ‘Even though children may consume an excess of energy, they may not be meeting all of their micronutrient needs.’\textsuperscript{16} In other words, children are overfed and undernourished. One expert has argued that a typical Western diet may provide enough magnesium to avoid frank magnesium deficiency, but it is unlikely to maintain high-normal magnesium levels and provide optimal risk reduction from coronary artery disease and osteoporosis. That is, ‘Various studies have shown that at least 300 mg magnesium must be supplemented to establish significantly increased serum magnesium concentrations...’\textsuperscript{17} In other words, most people need an additional 300 mg of magnesium per day in order to lower their risk of developing numerous chronic diseases. So while the recommended daily allowance (RDA) for magnesium (between 300 and 420 mg/day for most people) may prevent frank magnesium deficiency, it is unlikely to provide optimal health and longevity, which should be the ultimate goal.

Importantly, much of the population may not even be meeting the RDA for magnesium. For example, the average magnesium intake in men and women in Taiwan is only 250 mg and 216 mg, respectively, or 68%–70% of the recommended dietary reference intake.\textsuperscript{17} The authors of the study concluded: ‘Taiwanese elderly persons had suboptimal levels of dietary magnesium intake, which although may be sufficient to avoid overt magnesium deficiency, may not be sufficient to reduce the risk of diabetes in the elderly.’\textsuperscript{17} The National Nutrition Survey in Japan found that for people 15–49 years old the intake of magnesium was below the Japanese RDA.\textsuperscript{18} Moreover, around half (48%) of the US population consumes less than the recommended amount of magnesium from food.\textsuperscript{19} The US Department of Agriculture states that the average magnesium intake in women and men is 228 mg/day and 323 mg/day, respectively. Based on these data, one group of authors noted: ‘These intake levels suggest that a substantial number of people may be at risk for Mg deficiency, especially if concomitant disorders and/or medications place the individual at further risk for Mg depletion’.\textsuperscript{2} The most recent published review on magnesium concluded: ‘Approximately 50% of Americans consume less than the Estimated Average Requirement (EAR) for magnesium, and some age groups consume substantially less.’\textsuperscript{20}

Lakshmanan et al collected daily food records for 1 year in 34 men and women. They found that the mean magnesium intake was 323 mg/day and 234 mg/day in men and women, respectively (around 4 mg/kg/day). Despite this level of intake, the overall patient population was in negative magnesium balance (−32 and −25 mg/day, respectively).\textsuperscript{21} Moreover, 75% of women consumed less than the RDA (300 mg/day) and only one out of the eighteen women were in equilibrium. Considering that the average intake of magnesium in the USA is around 228 mg/day in women and 260 mg/day in men,\textsuperscript{12} a large percentage of Americans may be at risk of negative magnesium balance. Indeed, ‘Only American diets containing more than 3000 kcal/day may provide 300 mg or more magnesium.’\textsuperscript{21} Another long-term study lasting 50 weeks found that somewhere between 180 mg and 320 mg of magnesium/day is required in order to maintain positive magnesium balance.\textsuperscript{22} And since many individuals may be consuming below 320 mg/day of magnesium, this poses a major public health threat.

The data are consistent around the world that magnesium intake may be inadequate. Indeed, the intake of magnesium in Germany was determined to be only 200 mg for women and 250 mg for men.\textsuperscript{2} In Kiev a study on 780 men aged 20–59 found that the overall population consumed insufficient magnesium from food rations (10% less than the recommended value). The authors also found a correlation between the low magnesium consumption in food and the prevalence of risk factors for ischaemic heart disease, such as hyperlipoproteinemia, arterial hypertension and body weight.\textsuperscript{24} In 2004, Durlach concluded: ‘About 20% of the population consumes less than two-thirds of the RDA for Mg. Women, particularly, have low intakes. For example, in France, 23% of women and 18% of men have inadequate intakes. Mg deficiency during pregnancy can induce maternal, fetal, and pediatriic consequences that might last throughout life.’\textsuperscript{25} The median magnesium intake in an elderly population (832 subjects aged 70 years or older) in Southern France was also found to be below the RDA.\textsuperscript{26} Another French study on 2373 subjects (4–82 years of age) noted that 71.7% of men and 82.5% of women had an inadequate magnesium intake.\textsuperscript{27}

MAGNESIUM DEFICIENCY

‘Hypomagnesemia is a relatively common occurrence in clinical medicine. That it often goes unrecognized is due to the fact that magnesium levels are rarely evaluated since few clinicians are aware of the many clinical
states in which deficiency, or excess, of this ion may occur’. 28

In developed countries, older data estimated that the prevalence of marginal magnesium deficit is 15%–20% of the population.13 This corroborates more recent data indicating that around 10%–30% of a given population has subclinical magnesium deficiency based on serum magnesium levels<0.80 mmol/L.29 The 2006 National Health and Nutrition Survey found low serum concentrations of magnesium in 36.3% and 31% of female and male Mexican adults, respectively.30 The authors of the study concluded: ‘Low serum concentrations of...magnesium are published for the first time and show significant prevalence of deficiencies’,30 and up to 20% of the general population has low serum magnesium levels.31 A systematic review of 37 articles discovered that magnesium deficiency was a possible public health concern for older adults.32

Magnesium deficiency has been found in 84% of postmenopausal women with osteoporosis diagnosed by low magnesium trabecular bone content and Thoren’s magnesium load test.33 Among apparently healthy university students in Brazil, 42% were found to have subnormal magnesium status (based on plasma or erythrocyte magnesium levels).15 The average magnesium intake was only around 215 mg/day. Magnesium depletion has been found in 75% and 30.8% of patients with poorly controlled type 2 diabetes based on serum and intracellular magnesium status, respectively.34

Magnesium deficiency can be present despite normal serum magnesium levels. 6 Approximately 20% of 381 unselected elderly men and women (most of them in their 80s) were found to have low erythrocyte potassium and magnesium levels. The authors of the study concluded: ‘This study underlines the large prevalence of magnesium and potassium deficiencies in the elderly’.35 Another study concluded: The commonly designated low limit of the normal range...is below levels that exist in patients with marginal deficiencies that can predispose to development of pathologic findings, so that the prevalence and importance of this disease is insufficiently considered...It is a statistical error to use the confidence limits of the normal population as the exclusion limit for those with abnormal Mg status’.36 In other words, our normal range of serum magnesium is inaccurate and that serum magnesium levels at the lower end of normal likely suggest marginal magnesium deficiency.29 Indeed, ‘The magnesium content of the plasma is an unreliable guide to body stores: muscle is a more accurate guide to the body content of this intracellular cation’.37

Another study highlighting the discrepancy between serum and body magnesium levels concluded: ‘Although serum-K and serum-Mg values in patients receiving long-term treatment for hypertension or uncompensated heart disease usually are normal, muscle-Mg and muscle-K contents are reduced in around 50% of these patients...Evaluation of the K and Mg status during diuretic treatment should be preferentially based on tissue determinations. The muscle biopsy method is rapid, reliable and may reveal conditions of deficiency...oral supplements of Mg have proved to be adequate to restore the normal K/Mg status’.38

Among critically ill postoperative patients, 36.5% were found to have magnesium deficiency based on ionised magnesium levels in red blood cells.39 In one study of patients from a medical intensive care unit (ICU), 65% had hypomagnesaemia. The author concluded: ‘The prevalence of normomagnesemic Mg deficiency in critically ill patients may be even higher (than 65%, my insertion) and may contribute to the pathogenesis of hypocalcemia, cardiac arrhythmias and other symptoms of Mg deficiency’.40 Finally, 6.9%–11% of hospitalised patients have been noted to have hypomagnesaemia on routine exam posing on unrecognised need.41

The overall incidence of hypomagnesaemia in one study was noted to be between 5% and 8% of the overall population, and in young women (aged 18–22) the incidence was approximately 20%.5 One of the largest studies, a cross-sectional study in an unselected population of more than 16 000 subjects in Germany, found a prevalence of hypomagnesaemia (magnesium levels below 0.76 mmol/L) of 14.5%.3 42 Over 15% of hospitalised elderly patients have been found with low serum magnesium levels.43 Another study noted: ‘At ICU admission 52.5% had total hypomagnesemia and 13.5% total hypermagnesemia; with respect to the Mg(2+) 9.7% showed ionized hypomagnesemia and 23.6% ionized hypermagnesemia. Patients who developed ionized hypermagnesemia had higher mortality than patients without ionized hypermagnesemia development (P=0.04)’.44 And it has been noted that ‘Hypomagnesaemia detected at the time of admission of acutely ill medical patients is associated with an increased mortality rate for both ward and medical ICU patients’.45 Magnesium depletion is present in about half of all ICU patients.46 More than 50% of those hospitalised with either of the following conditions are likely to be magnesium-deficient based on an intravenous retention >20%: hypertension, coronary artery disease, cerebrovascular event, gastrointestinal issues or alcoholic liver.47

Based on 183 peer-reviewed studies published from 1990 to 2008, one group of authors concluded: ‘The perception that ‘normal’ serum magnesium excludes deficiency is common among clinicians. This perception is probably enforced by the common laboratory practice of highlighting only abnormal results. A health warning is therefore warranted regarding potential misuse of ‘normal’ serum magnesium because restoration of magnesium stores in deficient patients is simple, tolerable, inexpensive and can be clinically beneficial’.48 One study found that 10 out of 11 apparently healthy women were magnesium-deficient based on the oral magnesium load test. The authors concluded: ‘The results showed there are more frequent deficiencies of magnesium in organisms than it is generally assumed’.49 Another study showed that 37.6% of patients with type...
2 diabetes and 10.9% of age-matched and sex-matched healthy controls have low plasma magnesium levels.\\(^{50}\)

Of patients with severe chronic airway obstruction, 11.6% have serum magnesium levels less than the lower normal limit. The authors of the study concluded: ‘…routine serum magnesium determination is recommended in patients with chronic obstructive lung disease taking diuretic drugs or corticosteroids.\\(^{51}\)’

Hypomagnesaemia was identified in 47% of 1033 samples based on both routine magnesium determinations as well as physician-initiated requests for magnesium measurements.\\(^{52}\) Importantly, only 10% of the hypomagnesaemia findings were found by physician-initiated requests, underscoring the fact that low magnesium blood levels are an overlooked issue by medical doctors.

About 80% of patients with hypertension treated for at least 6 months with either hydrochlorothiazide or a single non-diuretic drug have been found to have magnesium depletion based on retention of a parenterally administered magnesium load.\\(^{53}\) More troubling is that despite being magnesium-depleted, patients treated with hydrochlorothiazide had high normal serum magnesium. This study underlines how patients can have normal or even higher magnesium levels in the blood despite magnesium depletion. Another study confirmed these findings that ‘thiazides induce a magnesium depletion not detectable by monitoring serum levels’.\\(^{54}\) There is a correlation between low magnesium bone concentrations and increased magnesium retention after an intravenous magnesium load, suggesting that magnesium is retained in the bone after the test.\\(^{55}\)

After several weeks of strenuous physical activity, serum magnesium can increase with no change in erythrocyte magnesium levels despite a reduction in mononuclear cell magnesium levels. The authors of a study concluded that the reduction in mononuclear cell magnesium content ‘reflects a reduction in exchangeable magnesium body stores, and the onset of a magnesium deficiency state’.\\(^{56}\) This study also indicates that just 6–12 weeks of strenuous physical activity can lead to magnesium deficiency. Another study concluded: ‘Serum and urinary magnesium concentrations decrease during endurance running, consistent with the possibility of magnesium deficiency. This may be related to increased demand in skeletal muscle’.\\(^{57}\)

One study found low levels of erythrocyte magnesium in 119 of 179 (66%) patients admitted consecutively to the ICU.\\(^{58}\) The prevalence of hypomagnesaemia at ICU admission has been estimated at around 51.3%, with a prevalence of ionised hypomagnesaemia at ICU admission ranging between 14.4% and 22%.\\(^{44}\)

While a normal serum magnesium is considered to be 0.7–1 mmol/L, the optimal serum magnesium concentration has been proposed to be >0.80 mmol/L.\\(^{59}\) Chronic latent magnesium deficiency has been defined as ‘…a serum magnesium concentration of between 0.75 and 0.849 mmol/L (within the reference interval), with a positive magnesium load test indicating magnesium deficiency’.\\(^{14}\)

**In summary**

‘Abnormalities of serum Mg may be the most underdiagnosed serum electrolyte abnormality in clinical practice today. The incidence appears to range from 12.5% to 20% on routine determination’.\\(^{41}\)

**‘NORMAL’ SERUM MAGNESIUM LEVELS**

0.75–0.95 mmol/L\(^{29}\)

- A serum magnesium <0.82 mmol/L (2.0 mg/dL) with a 24-hour urinary magnesium excretion of 40–80 mg/day is highly suggestive of magnesium deficiency.\\(^{29}\)
- One group of experts has recommended magnesium supplementation in subjects experiencing symptoms that reflect magnesium deficiency if the serum level is below 0.9 mmol/L,\\(^{36}\) with levels less than 0.8 mmol/L necessitating magnesium.
- Serum magnesium levels above 0.95 mmol/L may indicate hypermagnesaemia.

**DIETARY FACTORS AFFECTING MAGNESIUM STATUS**

‘Although magnesium intakes have been gradually falling since the beginning of the century, there were sharply increased intakes of nutrients that increased its requirements [particularly high vitamin D and phosphorus intake]…The major source of phosphorus derives from soft drinks that contain phosphoric acid, the consumption of which has been rising markedly in the last quarter of a century’.\\(^{60}\)

Since 1940 there has been a tremendous decline in the micronutrient density of foods. In the UK for example, there has been loss of magnesium in beef (−4 to −8%), bacon (−18%), chicken (−4%), cheddar cheese (−38%), Parmesan cheese (−70%), whole milk (−21%) and vegetables (−24%).\\(^{51}\) The loss of magnesium during food refining/processing is significant: white flour (−82%), polished rice (−83%), starch (−97%) and white sugar (−99%).\\(^{12}\) Since 1968 the magnesium content in wheat has dropped almost 20%, which may be due to acidic soil, yield dilution and unbalanced crop fertilisation (high levels of nitrogen, phosphorus and potassium, the latter of which antagonises the absorption of magnesium in plants).\\(^{62}\) One review paper concluded: ‘Magnesium deficiency in plants is becoming an increasingly severe problem with the development of industry and agriculture and the increase in human population’.\\(^{62}\) Processed foods, fat, refined flour and sugars are all devoid of magnesium, and thus our Western diet predisposes us to magnesium deficiency. Good dietary sources of magnesium include nuts, dark chocolate and unrefined whole grains.

Increased calcium and phosphorus intake also increases magnesium requirements and may worsen or precipitate magnesium deficiency.\\(^{53–55}\) Dairy, especially cheese, has a very high phosphorus to magnesium (Mg) ratio. For
example, cheddar cheese has a phosphorus:magnesium ratio of ~18 and a calcium:magnesium ratio of ~26, whereas pumpkin seeds have a phosphorus:magnesium ratio of 0.35 and a calcium:magnesium ratio of 0.21. Some have argued that the optimal dietary calcium:magnesium ratio is close to 2:1.

The amount of dietary magnesium required to maintain positive balance depends on numerous factors including the patient population as well as dietary and lifestyle choices. Indeed, magnesium balance decreases when calcium intake is over 10 mg/kg/day. Thus, the minimum required magnesium intake to maintain positive balance is not universal. Indeed, ‘Magnesium, like other dietary components, interacts with several nutrients and its requirement is modified not only by their levels but also by their form or type. The American diet is low in calcium and fiber as well as in magnesium, and high in protein and phosphorus’. Excess calcium, phosphorus and vitamin D may also lead to increased magnesium loss increasing magnesium requirements.

The phosphate to calcium ratio in the USA during 1932–1939 was approximately 1.2:1, rising to 4:1 in those who substituted the intake of soda for milk, but other data suggest that the phosphate:calcium ratio is around 1.5:1. Nonetheless, the most dramatic change that has occurred since the early 1900s until now regarding phosphate, calcium and magnesium has been a reduction in magnesium intake, going from around 500 mg/day to an average of 250 mg/day. Thus, the calcium:magnesium ratio has increased from approximately 2:1 to 5:1, and the phosphate:magnesium ratio has increased from 1.2:1 to around 7:1. The increase in dietary phosphate has come from phosphate additives, found in many food items but especially processed meats, as well as from phosphoric acid found in soft drinks.

One group of authors concluded: ‘The prevalence and incidence of type 2 diabetes in the United States increased sharply between 1994 and 2001 as the ratio of calcium-to-magnesium intake from food rose from ~3.0 to >3.0’. Another group of authors noted a 3.25-fold increased risk of diabetes at plasma magnesium levels <0.863 mmol/L (despite 0.75 mmol/L being considered a ‘normal’ level). In other words, patients with diabetes appear to be magnesium-deficient and magnesium deficiency likely increases the risk of diabetes.

Dietary aluminium may lead to magnesium deficit by reducing the absorption of magnesium by approximately fivefold, reducing magnesium retention by 41% and causing a reduction of magnesium in the bone. And since aluminium is widely prevalent in modern-day society (such as in aluminium cookware, deodorants, over-the-counter and prescription medications, baking powder, baked goods, and others), this could be a major contributor to magnesium deficiency. In fact, an area near a Skawina aluminium plant in Poland was found to have a lower percentage of people with normal magnesium levels in red blood cells and urine compared with those in Chorzów.

A common misconception is that consuming phytate-rich foods can lead to nutrient deficiencies particularly magnesium depletion via binding by phytic acid. However, urinary magnesium excretion will drop to compensate for a reduction in bioavailable magnesium. And most high-phytate foods are also good sources of magnesium (grains and beans are good examples). Thus, it is unlikely that consuming foods high in phytate will lead to magnesium depletion. However, a vitamin B6-deficient diet can lead to a negative magnesium balance via increased magnesium excretion.

**MAGNESIUM BALANCE**

A study of 11 postmenopausal women (aged 49–71 years) found that an intake of 107 mg/day of magnesium was inadequate for maintaining positive magnesium balance. A placebo-controlled trial in young women who were supplemented with 100 mg magnesium per day (basal magnesium intake 250 mg) was inadequate for positive or even zero magnesium balance even though the supplemented women had a higher magnesium excretion in urine, indicating a higher total absorption. In other words, young women may be in negative magnesium balance despite consuming 350 mg of magnesium per day. However, one double-blind metabolic balance study in postmenopausal Caucasian women showed that 318 mg of magnesium per day was enough to remain in positive balance, but 118 mg/day was inadequate. A more recent balance study in postmenopausal women found that while a diet containing 399 mg of magnesium per 2000 kcal was able to produce a positive magnesium balance, a diet containing ~100 mg of magnesium per 2000 kcal was inadequate. Other data have found negative magnesium balance in men with osteoporosis or psychoneurosis consuming 240 mg/day of magnesium.

Another study noted negative magnesium balance (~122 mg) in those consuming 322 mg/day of magnesium on top of a high-fibre diet. In other words, context matters (overall dietary pattern, patient population and background medication).

One of the most comprehensive reviews in the literature on this subject suggests that in healthy adults only around 180 mg of magnesium per day is required to maintain balance in healthy individuals (even when taking into account magnesium sweat losses). This analysis pooled magnesium data from 27 different tightly controlled balance studies (lasting more than 27 days) conducted in the USA. However, it must be noted that this analysis does not take into account the numerous disease states, medications, stress and dietary factors that increase magnesium requirements.

Based on the National Health and Nutrition Examination Survey (NHANES) data, 64% of women aged 51–70 years old do not achieve the EAR for this age group (265 mg/day), with an estimated average magnesium intake of just 246 mg/day (NHANES 2001–2002) and only 238 mg/day (NHANES 1999–2000). Magnesium
intake for Mexican and African–American women of the same age group is even lower (185 mg/day and 169 mg/day, respectively, and 176 mg/day and 150 mg/day in those reporting no dietary supplement use). Thus, the elderly population is especially at risk of magnesium deficiency due to low intake but also increased risk for chronic diseases that predispose to magnesium deficiency (ageing also reduces magnesium absorption from the diet, ie, achlorhydria). Table 1 covers the magnesium requirements from older balance studies.

### CAUSES OF MAGNESIUM DEFICIENCY

Numerous factors can lead to magnesium deficiency, such as kidney failure, alcohol consumption and malabsorption issues (magnesium is absorbed in the small intestine and in the colon; thus, patients with intestinal or colon damage such as Crohn’s disease, irritable bowel syndrome, coeliac disease, gastroenteritis, idiopathic steatorrhoea, ulcerative colitis, resection of the small intestine, ileostomy patients or patients with ulcerative colitis may have magnesium deficiency). Renal tubular acidosis, diabetic acidosis, prolonged diuresis, acute pancreatitis, hyperparathyroidism and primary aldosteronism can also lead to magnesium deficiency. A meta-analysis of 13 studies in almost 5500 patients found that magnesium levels were significantly lower in patients with metabolic syndrome versus controls. The intravenous magnesium tolerance test has confirmed that children with type 1 diabetes have intracellular magnesium deficiency. This is likely due to osmotic diuresis and increased magnesuria caused by high glucose levels and damage to the renal tubules. Patients with type 2 diabetes have been found with lower magnesium levels compared with healthy controls (0.79 mmol/L vs 0.88 mmol/L). Conversely, magnesium levels are relatively stable and decline in severe deficiency. Another study concluded ‘…athletes suffer from a magnesium deficiency, partially due to physical exercise’. At a minimum, approximately 15 mg of magnesium is lost in sweat per day, but losses are probably greater especially in conditions of increased perspiration (exercise, heat and humidity). Box 1 covers renal magnesium wasting. Box 2 provides a comprehensive list of potential causes of magnesium deficiency.

### CLINICAL SIGNS OF MAGNESIUM DEFICIENCY

‘…magnesium is essential for the normal metabolism of potassium and of calcium…the occurrence in clinical situations of otherwise unexplained hypokalemia and hypocalcaemia should suggest the possibility of significant magnesium depletion’. Among the most common laboratory signs of magnesium deficiency are low potassium and calcium levels, as well as low urine and/or faecal magnesium. The most common neurological side effect with magnesium depletion is the Trousseau sign; that is, ‘To elicit the sign, a blood pressure cuff is placed around the arm and inflated to a pressure greater than the systolic blood pressure and held in place for 3 min. This will occlude the brachial artery. In the absence of blood flow, the patient’s hypocalcaemia and subsequent neuromuscular irritability will induce spasm of the muscles of the hand and forearm. The wrist and metacarpophalangeal joints flex, the DIP and PIP joints extend, and the fingers adduct’. Other signs of magnesium deficiency included tremor, fasciculations (‘a brief spontaneous contraction that affects a small number of muscle fibres’), spontaneous carpopedal spasm (painful cramps of the muscles in your hands and feet) and generalised spasticity. Other clinical features of magnesium deficiency include mental disturbances such as depression, confusion, agitation, hallucinations, weakness, neuromuscular irritability (tremor), athetoid movements and convulsive seizures. A full list of potential clinical and lab signs of magnesium deficiency are summarised in box 3 and box 4.

---

**Table 1** Magnesium requirements based on older balance studies

| Age           | Requirement     |
|---------------|-----------------|
| Infants       | 150–200 mg/day  |
| Children      | 200–250 mg/day  |
| Adults        | 250–300 mg/day  |
| Lactating women | 400 mg/day     |

**Box 1** Renal magnesium wasting

- Diagnosis: urinary magnesium excretion >24 mg/day in the presence of hypomagnesaemia (<0.7 mmol/L).
- Causes
  - Bartter’s syndrome.
  - Gitelman’s syndrome.
  - Diabetes.
  - Hypercalcemia.
  - Diuretics.
  - Cisplatinum.
  - Aminoglycosides.
  - Pentamide.
  - Cyclosporin.
  - Calcitriol deficiency.

---
Magnesium deficiency is extremely hard to diagnose since symptoms are generally non-specific, there are numerous contributing factors, and there is no simple easy way to diagnose magnesium deficiency. However, one study concluded: 'There is Mg deficiency in many patients with variant angina and it is corrected after treatment with calcium antagonists'. The authors noted that the mean 24-hour magnesium retention of an intravenous magnesium load was 60% in those with variant angina versus 36% in controls despite both groups having the same normal serum magnesium levels (2.1 mg/dL).

Gastrointestinal loss of magnesium can be determined by increased renal conservations of magnesium measured by a fractional magnesium excretion of less than 2%. Renal magnesium wasting can be determined by a fractional magnesium excretion above 2% in patients with normal renal function.

**Thoren’s intravenous magnesium load test (16 hours)**

Thoren has suggested that if less than 70% of a 30 mEq (~365 mg) to 40 mEq (~486 mg) of parenteral magnesium given over an hour to an adult is excreted in the following 16 hours, this may indicate magnesium deficiency. In other words if you give ~400 mg of magnesium intravenously over 1 hour, if 70% or more of that dose (so 280 mg or more) is not excreted in the urine over the next 16 hours, this likely indicates magnesium deficiency even in the presence of normal magnesium levels.

**Thoren’s intravenous magnesium load test for diagnosing magnesium deficiency**

1. Provide ~360–480 mg of magnesium intravenously over 1 hour

**DIAGNOSING MAGNESIUM DEFICIENCY**

‘The existence of subacute or chronic magnesium deficiency is difficult to diagnose. Because the tissues damaged by magnesium depletion are those of the cardiovascular, renal and the neuromuscular systems, early damage is not readily detectable. It is postulated that long-term suboptimal intakes of magnesium may participate in the pathogenesis of chronic diseases of these systems.’
2. If <70% of the magnesium load comes out in the urine over 16 hours, this is highly suggestive of magnesium deficiency.

Healthy subjects have been noted to have an intravenous magnesium load retention between 2% and 8%. Corroborating these findings are another study that found an average magnesium retention from an intravenous load to be 6.3% in healthy patients aged 18–66 years old. The 97.5% fractile was retention of 27.5%. A large percentage of patients who are considered healthy can be magnesium-deficient. Based on these results an intravenous magnesium load retention above 27.5% is highly suggestive of magnesium deficiency. In fact, one study in healthy patients found a 6% 24-hour magnesium retention after an intravenous magnesium load in young controls but a 28% retention in the elderly, suggesting that a large percentage of the elderly population is magnesium-deficient. The authors of the study concluded: ‘This study suggests that a significant subclinical magnesium deficit, not detected by serum magnesium, was present in many of these healthy elderly subjects. Magnesium supplementation improved magnesium status and renal function’. If using 2 SD above the mean intravenous magnesium retention in normal younger healthy patients, an abnormally high magnesium retention would be approximately 28%. This suggests that about half of all elderly patients may be magnesium-deficient (a level very close to the 27.5% retention level found as the upper bound in healthy patients aged 18–66 years).

The intravenous magnesium load test has been given as 0.2 mmol/kg MgSO4 over 4 hours (or around 340 mg of magnesium for a 70 kg person). One procedure has given magnesium sulfate MgSO4 (0.2 mmol/kg body weight) in 250 mL of 5% dextrose in water at 09:00 over 4 hours. Twenty-four-hour urine samples were then collected starting from the initiation of the infusion to determine 24-hour urinary magnesium excretion. Baseline 24-hour urinary magnesium excretion was then subtracted from postinfusion 24-hour urinary magnesium excretion. The magnesium retention was then calculated by the total amount of magnesium infused – (postinfusion 24-hour urinary magnesium – baseline 24-hour urinary magnesium) × 100/total amount of magnesium infused. Box 5 provides measurements to diagnose magnesium deficiency from best to worst. Box 6 provides a summary of causes of hypermagnesaemia. Box 7 covers treatments for hypermagnesaemia.

**TREATMENT OF MAGNESIUM DEFICIENCY**

One group of authors concluded: ‘When magnesium substitution is started, the minimum dose to be applied is 600 mg magnesium per day. The therapy should proceed...
for more than one month, and then continue with a dose that holds the serum value not lower than 0.9 mmol/L magnesium. The authors noted that using a cut-off of 0.75 mmol/L for magnesium deficiency misses 50% of those with true magnesium deficiency.

**Box 6 Causes of hypermagnesaemia**

- Oversupplementation (mainly from magnesium containing antacids).
- Kidney damage.
- Inflammation and cellular injury (significant increases in total and ionised magnesium in animals during endotoxin challenge).

**Box 7 Treatment of hypermagnesaemia**

- Diuresis or dialysis (to increase renal elimination of magnesium).
- Supportive care.

**CONSEQUENCES OF MAGNESIUM DEFICIENCY**

**Hypertension**

‘Magnesium status has a direct effect upon the relaxation capability of vascular smooth muscle cells and the regulation of the cellular placement of other cations important to blood pressure - cellular sodium/potassium (Na:K) ratio and intracellular calcium (iCa(2+)). As a result, nutritional magnesium has both direct and indirect impacts on the regulation of blood pressure and therefore on the occurrence of hypertension’.  

It must be remembered that there is magnesium-ATP-driven sodium-potassium pump and calcium pump. Magnesium deficiency leads to dysfunction of the Na-K-ATPase depleting intracellular K and increasing intracellular sodium and calcium in cardiac and smooth muscle cells. This can cause vasoconstriction of venous smooth muscles and arteries causing hypertension. Magnesium deficiency may also predispose to an increased response to vasoconstrictors, such as angiotensin II and catecholamines.

Many patients with hypertension are treated with thiazide and loop diuretics, both of which deplete the body of magnesium, and giving patients with hypertension who are receiving long-term thiazide diuretics oral magnesium supplementation significantly reduces blood pressure. In fact, the high intracellular calcium induced by magnesium deficiency may induce both insulin resistance and hypertension. A meta-analysis of randomised, double-blind, placebo-controlled trials in normotensive and hypertensive adults found that 368 mg/day of magnesium for a median of 3 months significantly reduces systolic blood pressure by 2.00 mm Hg and diastolic blood pressure by 1.78 mm Hg. In fact, a meta-analysis of seven studies encompassing 135 patients with hypertension on antihypertensive medications with a mean starting blood pressure >155 mm Hg found that magnesium supplementation reduced blood pressure by −18.7/−10.9 mm Hg. Another meta-analysis of 22 trials using a mean dose of 410 mg of magnesium found a significant reduction in systolic (3–4 mm Hg) and diastolic (2–3 mm Hg) blood pressure. The effect on blood pressure was greater when magnesium doses >370 mg/day were used.

Low magnesium levels can promote endothelial cell dysfunction, potentially increasing the risk of thrombosis and atherosclerosis. Magnesium deficiency also promotes a proatherogenic phenotype in endothelial cells. Hypomagnesaemia can impair the release of nitric oxide from the coronary endothelium, while magnesium therapy can improve endothelium-dependent vasodilation in patients with coronary artery disease. Since nitric oxide is both a vasodilator and an

**Box 5 Measurements to diagnose magnesium deficiency (best to worst)**

**Reliable methods**

- Retention of magnesium load (intravenous or oral) after its administration is likely the best indicator of magnesium deficiency. However, the retention test assumes normal kidney function for intravenous magnesium loads and normal gastrointestinal and renal function for oral load tests and is cumbersome and invasive.
- Mononuclear cell magnesium and muscle magnesium content (muscle biopsy).

**Less reliable methods**

- Hair magnesium content (one study concluded: ‘magnesium hair concentration may be an easier, cheaper and less invasive indicator of body magnesium depletion’).
- Bone magnesium (magnesium depletion in the coccyx may indicate magnesium deficiency).
- Ratio of ionised magnesium to total magnesium (serum or plasma).
- Ionised magnesium levels (serum or erythrocytes, ionised magnesium is the physiologically active magnesium not bound to proteins). However, this biomarker is controversial and not always available in clinical labs and hard to measure reliably.
- Lymphocyte magnesium.
- Urinary or faecal magnesium excretion (low or high levels may indicate deficiency).
- Urinary fractional magnesium excretion (some authors have suggested >2% in those with normal kidney function).
- Total erythrocyte magnesium levels (magnesium deficiency has been suggested when erythrocyte magnesium levels are <1.65 mmol/L).
- Total serum magnesium levels.
- It is important to note that choosing only one of the aforementioned methods of measuring magnesium deficiency is not appropriate for diagnosing magnesium deficiency. In general, either symptoms of magnesium deficiency must accompany the more reliable methods to diagnose magnesium deficiency (eg, intravenous/oral magnesium load, mononuclear cell or muscle), or two or more of the reliable measurements (eg, intravenous/oral magnesium load, mononuclear cell or muscle) should be used in supporting a diagnosis of magnesium deficiency.
inhibitor of platelet aggregation, this makes magnesium supplementation a promising therapy in the treatment of hypertension and coronary artery disease. Indeed, magnesium therapy may enhance prostacyclin release from the vascular wall.106

**Atherosclerosis and calcifications**

Magnesium deficiency and magnesium depletion in soft tissues can cause calcifications in the heart, liver and skeletal muscles.107 Magnesium deficiency may be a leading cause of kidney disease as it leads to swelling of the tubular epithelium, apatite crystal deposition in the proximal convoluted tubules, loops of Henle, collecting tubules and in the pars recta.108 Thus, magnesium deficiency damages the kidneys due to calcium deposits and may cause numerous electrolyte abnormalities (a common problem in patients with chronic kidney disease). Other studies in animals show that magnesium deficiency causes cardiac necrosis and calcifications.109 Magnesium deficiency can calcify the descending limb of the loop of Henle, which may lead to dehydration and volume depletion by reducing water reabsorption.108 A greater intake of magnesium is associated with having a lower risk of an elevated coronary artery calcification score,110 and supplementing with magnesium has been found to improve endothelial function in patients with coronary artery disease.111

One animal study noted: ‘...the degree of lipid deposition in the aorta of cholesterol-fed rabbits can be significantly enhanced by feeding a magnesium-deficient diet...’ The calcification of the inflammatory granuloma of the aortas and the atrophy and degeneration of muscle fibres with inflammatory connective tissue proliferation in the myocardium and in the stomach and skeletal muscles were only observed in rabbits fed a magnesium deficient diet.112 In other words, eating a diet deficient in magnesium predisposes to atherosclerosis, calcification of the aorta, degeneration of myocardial muscle fibres and inflammatory connective tissue throughout the body. This study suggests that low magnesium intake increases inflammation.

Inadequate dietary magnesium intake increases atherosclerotic plaque development in rabbits113 and induces myocardial fibrosis similar to what is found in human cardiomyopathy endomyocardial fibrosis.114 A diet deficient in magnesium in the Cebus monkey causes an increase in serum cholesterol, ST segment depression and atherosclerotic plaques in the aorta,115 whereas magnesium fortification in drinking water inhibits atherosclerosis in female and male Low-density lipoprotein (LDL)-receptor-deficient mice fed a high-cholesterol diet.116,117

Magnesium treatment for 3 months in patients with ischaemic heart disease increases the apolipoprotein A1:apolipoprotein B ratio by 13%, decreases the apolipoprotein B concentrations by 15%, and decreases very-low-density lipoprotein concentrations by 27%.118 Magnesium therapy also tended to increase high-density lipoprotein. The authors of the study concluded: ‘...magnesium deficiency might be involved in the pathogenesis of ischemic heart disease by altering the blood lipid composition in a way that disposes to atherosclerosis’.118 In hypomagnesaemic kidney transplant recipients, magnesium supplementation significantly decreases total cholesterol, low-density lipoprotein and total cholesterol:high density lipoprotein ratio.119 Magnesium deficiency may enhance vascular endothelial injury, promoting the development and progression of atherosclerosis.120

Magnesium deficiency may supersaturate bodily fluids with octacalcium phosphate calcifying soft tissues, whereas magnesium therapy may stop or even prevent soft tissue calcifications.121 Magnesium deficiency in Yorkshire swine induces numerous calcifications and smooth muscle cell degeneration, and promotes atherosclerosis in combination with an atherogenic diet.122 Hamsters fed a magnesium-deficient diet develop myocardial necrosis, calcifications and cardiomyopathy. These effects of magnesium deficiency seem to be secondary to the inhibition of the Na-K-ATPase and the calcium overload that follows in cardiac myocytes.123 Triglyceride-rich lipoproteins from magnesium-deficient rats are more susceptible to oxidation.124 Thus, magnesium deficiency predisposes to lipoprotein peroxidation and atherosclerosis. Perhaps most importantly, patients in the intensive cardiac care unit have been noted to have low blood mononuclear cell magnesium levels.125 The authors summarised their findings as the following: ‘We conclude that the incidence of intracellular Mg deficiency in patients with cardiovascular disease is much higher than the serum magnesium would lead one to suspect, and may contribute to clinical cardiovascular morbidity’.125

**Arrhythmias**

‘Although available on order by physicians, the lack of routine serum Mg analysis as part of the ‘electrolyte panel’ impedes the diagnosis of clinical Mg deficiency. Renal loss of Mg resulting from the widespread use of loop diuretics is responsible for significant numbers of patients with Mg deficiency and hypomagnesemia. Life-threatening cardiac arrhythmias and seizures represent the most serious manifestation of clinical hypomagnesemia and Mg depletion [...] Hypomagnesemia is one of the most frequent serum electrolyte abnormalities in current clinical practice. Routine inclusion of serum Mg analysis in the electrolyte panel will enhance the clinical recognition and treatment of hypomagnesemic Mg-depleted patients. Failure to respond to treatment of recurrent ventricular tachycardia/fibrillation to usual antiarrhythmic therapy in patients with acute myocardial infarction, idiopathic dilated cardiomyopathy, and congestive heart failure should alert the clinician to consider administering intravenous Mg’.126

As noted previously, magnesium deficiency reduces cardiac Na-K-ATPase, leading to higher levels of sodium and calcium and lower levels of magnesium and potassium in the heart. This increases vasoconstriction in the coronary arteries, which can induce coronary artery spasms,
myocardial infarction and arrhythmias. Considering that around 25% of all myocardial infarctions are not due to atherosclerotic plaque rupture, coronary artery spasm induced by magnesium deficiency may explain some of these events.

In one metabolic study of 22 postmenopausal women, a low-magnesium diet (containing around 130 mg/day) significantly increased both supraventricular and supraventricular plus ventricular beats based on Holter monitor. The authors of the study concluded: ‘The recommended dietary allowance of 320 mg/day seems correct; 130 mg is too little. Persons who live in soft water areas, who use diuretics, or who are predisposed to magnesium loss or ectopic beats may require more dietary magnesium than would others.’ Another study in postmenopausal women found that a low-magnesium diet (approximately 100 mg/day) can induce atrial fibrillation and increases glucose levels. Patients with diabetes mellitus and arrhythmia have been noted to have lower serum levels of ionised magnesium. Thus, it appears that low dietary intake of magnesium or low magnesium levels can predispose to arrhythmias. Diuretics and digoxin also cause magnesium depletion, making the heart more susceptible to the development of arrhythmias.

Hypomagnesaemia may induce arrhythmias including torsades de pointes ventricular tachycardia. Magnesium therapy may be useful in the treatment of refractory ventricular tachycardia, ventricular fibrillation, multifocal atrial tachycardia, atrial fibrillation and supraventricular tachycardia. A meta-analysis of 19 randomised trials using magnesium orotate found a significant reduction in first-degree mitral valve prolapse, grade 1 regurgitation, supraventricular and ventricular premature contraction, and paroxysmal supraventricular tachycardia.

Coronary artery disease

‘...low heart muscle magnesium may contribute to sudden death after myocardial infarction. Western diets are probably often low in magnesium, so that the magnesium in hard drinking water may help to protect its consumers from ischemic heart disease...Increasing the magnesium content of the diet may help to prevent ischemic heart disease, and there is already evidence that magnesium salts can have beneficial effects on established heart disease.’

Autopsy studies have revealed lower magnesium content in both infarcted and non-infarcted heart muscle in those who have died of a myocardial infarction. Furthermore, autopsy studies have noted that those dying from accidents have lower heart muscle magnesium in soft-water drinking areas versus those from hard-water areas. This suggests that patients who have lower than normal magnesium concentrations in their heart muscle may be more likely to die suddenly after a myocardial infarction. Indeed, there are numerous studies indicating an increased rate of death from heart disease in low-magnesium drinking water areas.

Magnesium is required for the formation and activation of ATP and is essential for heart muscle contraction and oxidative phosphorylation in heart mitochondria. There is also a rapid loss of myocardial magnesium during anoxia, suggesting that chronic angina leads to magnesium deficiency. Chipperfield and Chipperfield noted: ‘Magnesium-deficient diets...predispose animals to the development of myocardial fiber necrosis. Administration of magnesium salts has been shown to reverse many of the changes in animal models of heart disease...There is also good evidence from some animal studies that pretreatment with magnesium salts protects against many of the changes in the heart caused by anoxia...’ In other words, consuming a diet high in magnesium may prevent the harms from an acute ischaemic event.

Just 42–64 days on a diet low in magnesium (~101 mg/day) produced atrial fibrillation and flutter in three of five postmenopausal women (ages 47–75 years). Moreover, the arrhythmias responded quickly to magnesium supplementation. During the low-magnesium diet, glucose levels increased and red blood cell superoxide dismutase decreased. The authors of the study concluded: ‘A dietary intake of about 4.12 mmol (~101 mg/day, my insertion) Mg/8.4 MJ is inadequate for healthy adults and may result in compromised cardiovascular health and glycemic control in postmenopausal women.’

In a randomised, double-blind, placebo controlled study on 350 patients with acute myocardial infarction, intravenous magnesium sulfate given immediately after completion of thrombolytic therapy significantly reduced all-cause mortality (3.5% vs 9.9%, P<0.01) and ventricular arrhythmias (13% vs 48.6%, P=0.00001). There was also a numerical reduction in reinfarction (8.8% vs 12.7%, P value not significant).

Magnesium deficiency in swine leads to proaggregatory and procoagulation alterations, and in humans leads to increased thromboxane synthesis. In rats, magnesium deficiency increases thromboxane B2 outflow. Magnesium treatment has been found to inhibit thrombus formation (as measured by platelet-dependent thrombosis) in patients with stable coronary artery disease by 35%. These effects are additive to that of aspirin and are independent of platelet aggregation. One author concluded: ‘High dose of intravenous magnesium can inhibit thrombus formation and is associated with suppression of platelet aggregation. Magnesium treatment can dose-dependently inhibit a wide variety of agonists of platelet aggregation, such as thromboxane A2 and stimulate prostacyclin synthesis. The molecular basis for these effects is likely modulated via reduction of intracellular calcium mobilization’. Thus, magnesium may prevent thrombotic events and may also protect cardiac cells against ischaemia.

Platelet-dependent thrombosis is significantly higher in patients with stable coronary artery disease with low intracellular magnesium levels. Administration of

DiNicolantonio JJ, et al. Open Heart 2018;5:e000668. doi:10.1136/openhrt-2017-000668

Page 11

Coronary artery disease
intravenous magnesium to healthy volunteers significantly inhibits both ADP-induced platelet aggregation by 40% and binding of fibrinogen or surface expression of GP-140 by 30%. Thus, magnesium therapy also has antiplatelet effects. In rats, intravenous magnesium therapy inhibits arterial thrombi after vascular injury. All of these suggest that magnesium is an anti-thrombotic and antiplatelet agent and that magnesium deficiency may promote thrombosis. Furthermore, magnesium deficiency appears to be more prevalent in patients with coronary artery disease or ischaemic heart disease, suggesting a need for magnesium treatment.

Box 8 provides a summary of possible cardiovascular manifestations of magnesium deficiency.

CONCLUSION

Subclinical magnesium deficiency is a common and under-recognised problem throughout the world. Importantly, subclinical magnesium deficiency does not manifest as clinically apparent symptoms and thus is not easily recognised by the clinician. Despite this fact, subclinical magnesium deficiency likely leads to hypertension, arrhythmias, arterial calcifications, atherosclerosis, heart failure and an increased risk for thrombosis. This suggests that subclinical magnesium deficiency is a principal, yet under-recognised, driver of cardiovascular disease. A greater public health effort is needed to inform both the patient and clinician about the prevalence, harms and diagnosis of subclinical magnesium deficiency.

Contributors JJD performed the literature search and wrote the manuscript. JHO and WW edited the final manuscript.

Competing interests JJD is the author of The Salt Fix and operates the website thesaltfix.com.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement There are no additional data available for this paper.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
administered rare earth chloride through drinking water. *Biol Trace Elem Res* 1998;63:19–30.

115. Vitale JJ, Velez H, Guzman C, et al. Magnesium deficiency in the Cebus monkey. *Circ Res* 1963;12:642–50.

116. Sherrer Y, Shoenfeld Y, Shaihi A, et al. Suppression of atherogenesis in female low-density lipoprotein receptor knockout mice following magnesium fortification of drinking water: the importance of diet. *Pathobiology* 2000;68:93–8.

117. Sherrer Y, Shaihi A, Levkovitz H, et al. Magnesium fortification of drinking water suppresses atherogenesis in male LDL-receptor-deficient mice. *Pathobiology* 1999;67:207–13.

118. Rasmussen HS, Aurup P, Goldstein K, et al. Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled study. *Arch Intern Med* 1989;149:1050–3.

119. Gupta BK, Ghidini D, Tallis VA. Magnesium repletion therapy improved lipid metabolism in hypomagnesemic renal transplant recipients: a pilot study. *Transplantation* 1999;67:1485–7.

120. Cojocaru IM, Cojocaru M, Burcic C, et al. Serum magnesium in patients with acute ischemic stroke. *Rom J Intern Med* 2000;38:293–7.

121. Driessen FC, Verbeck RM. On the prevention and treatment of calcification disorders of old age. *Med Hypotheses* 1988;25:131–7.

122. Ito M, Toda T, Kummerow FA, et al. Effect of magnesium deficiency on ultrastructural changes in coronary arteries of swine. *Acta Pathol Jpn* 1986;36:225–34.

123. Ahmad A, Bloom S. Sodium pump and calcium channel modulation of Mg-deficiency cardiomyopathy. *Am J Cardiovasc Pathol* 1989;2:277–83.

124. Russeit P, Mazur A, Gueux E, et al. Triglyceride-rich lipoproteins from magnesium-deficient rats are more susceptible to oxidation by cells and promote proliferation of cultured vascular smooth muscle cells. *Magnes Res* 1995;8:151–7.

125. Ryzen E, Elkyam U, Rude RK. Low blood mononuclear cell magnesium in intensive cardiac care unit patients. *Am J Heart* 1986;111:475–80.

126. Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. *Ann Pharmacother* 1994;28:220–6.

127. Kubena KS, Durlach J. Historical review of the effects of marginal intake of magnesium in chronic experimental magnesium deficiency. *Magnes Res* 1990;3:219–26.

128. Klevay LM, Milne DB. Low dietary magnesium increases supraventricular ectopy. *Am J Clin Nutr* 2002;75:550–4.

129. Nielsen PH, Milne DB, Klevay LM, et al. Dietary magnesium deficiency induces heart rhythm changes, impairs glucose tolerance, and decreases serum cholesterol in post menopausal women. *Am J Coll Nutr* 2007;26:121–32.

130. Sasaki S, Oshima T, Matsuura H, et al. Abnormal magnesium status in patients with cardiovascular diseases. *Circ J* 2000;64:175–81.

131. Chipperfield B, Chipperfield JR. Magnesium and the heart. *Am J Heart* 1997;93:679–82.

132. Papacet J, Moral V, Recio J, et al. [Severe heart arrhythmia secondary to magnesium deletion. Torsade de pointes]. *Rev Esp Cardiol* 1999;52:29–31.

133. Iseri LT. Role of magnesium in cardiac tachyarrhythmias. *Am J Heart* 1990;65:K45–K50.

134. Torshin IY, Gromova OA, Kalacheva AG, et al. [Meta-analysis of clinical trials of cardiovascular effects of magnesium orotate]. *Ter Arkh* 2015;87:23–97.

135. Raghu C, Peddevsara Rao P, Seshagari Rao D. Protective effect of intravenous magnesium in acute myocardial infarction following thrombolytic therapy. *Int J Cardiol* 1999;71:209–15.

136. Serebruany VL, Herzog WR, Edenbaum LR, et al. Changes in the haemostatic profile during magnesium deficiency in swine. *Magnes Res* 1996;9:155–63.

137. Nadler JL, Buchanan T, Natarajan R, et al. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. *Hypertension* 1993;21:1024–9.

138. Soma M, Cunnane SC, Horrobin DF, et al. Effects of low magnesium diet on the vascular prostaglandin and fatty acid metabolism in rats. *Prostaglandins* 1988;36:431–41.

139. Mautar JP, Kantelip JP, Angeloud T, et al. [Cardiovascular pathology and magnesium]. *Therapie* 1993;48:599–607.

140. Shechter M, Merz CB, Rude RK, et al. Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. *Am J Heart* 2000;140:212–8.

141. Gawaz M, Ott I, Reininger AJ, et al. Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. *Thromb Haemost* 1994;72:912–8.
142. Mussolini L, Sironi L, Tedeschi L, et al. Magnesium inhibits arterial thrombi after vascular injury in rat: in vivo impairment of coagulation. *Thromb Haemost* 2001;86:1292–5.

143. Wannapil N, Pourgvarin N, Pokum S, et al. Serum magnesium in Thai coronary artery disease patients. *J Assoc Med Assoc Thailand* 2001;94(Suppl 3):66–71.

144. Ramosus HS, McNair P, Goransson L, et al. Magnesium deficiency in patients with ischemic heart disease with and without acute myocardial infarction uncovered by an intravenous loading test. *Arch Intern Med* 1988;148:329–32.

145. Sutton RA, Dokos P, Thapar S, et al. Abnormal renal magnesium handling. *Mineral Electrolyte Metab* 1993;19:232–40.

146. Tuso PJ, Nortman D. Renal magnesium wasting associated with acetonaminophen abuse. *Conn Med* 1992;56:421–3.

147. Delva P, Pastorci C, Degani M, et al. Intra lymphocyte free magnesium in patients with primary aldosteronism: aldosterone and lymphocyte magnesium homeostasis. *Hypertension* 2000;35:113–7.

148. Lalor BC, France MW, Powell D, et al. Bone and mineral metabolism and chronic alcohol abuse. *J Q Med* 1986;59:497–511.

149. Moutokalakis TD. Effects of aging, chronic disease, and multiple interventions on magnesium requirements. *Magnesium* 1987;6:5–11.

150. Fernández-Fernández FJ, Sesma P, Caimozos-Romero T, et al. Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. *Neth J Med* 2010;68:329–30.

151. Lipner A. Symptomatic magnesium deficiency after small-intestinal bypass for obesity. *Br Med J* 1977;1:148.

152. Johnson S. The multifaceted and widespread pathology of magnesium deficiency. *Med Hypotheses* 2001;56:63–70.

153. Lum G. Hypomagnesemia in acute and chronic care patient populations. *Am J Cardiol* 1992;79:827–30.

154. Rijnjan R, Socha J, Wojtasik A, et al. [Magnesium status in children and adolescents with celiac disease]. *Wiad Lek* 2001;54:277–85.

155. Normen L, Arildsen I, Lebeau A, et al. [Effects of aging, chronic disease, and management of hypomagnesemia]. *J Am Soc Nephrol* 2009;20:2291–5.

156. Nanji AA, Denegri JF. Hypomagnesemia associated with gentamicin therapy. *Drug Infor Clin Pharm* 1984;18:596–8.

157. Eloy JP, Hernandez A, Pock A, et al. Hypomagnesemia is a common complication of anticoagulant therapy. *Surg Gynecol Obstet* 1984;158:561–5.

158. Gluszek J, Raszewska-Wanic B, Grajek S, et al. [Magnesium deficiency in tubular acidoses]. *Wiad Lek* 1980;33:401–4.

159. Bianchetti MG, Oelticker OH, Lütschig J. Magnesium deficiency in primary distal tubular acidoses. *J Pediatr* 1993;122:833.

160. Brannan PG, Vergerne-Marini P, Pak CY, et al. Magnesium absorption in the human small intestine. Results in normal subjects, patients with chronic renal disease, and patients with absorptive hypercalciuria. *J Clin Endocrinol Metab* 1990;76:549–53.

161. Kodama N, Nishimuta M, Suzuki K. Negative balance of calcium and magnesium under relatively low sodium intake in humans. *J Nutr Sci Vitaminol* 2003;49:201–9.

162. Sjögren A, Florin Chastre J, Nilsson P. Evaluation of magnesium status in Crohn’s disease as assessed by intracellular analysis and magnesium infusion. *Scand J Gastroenterol* 1988;23:555–61.

163. Vitale C, Marangella M, Petrarulo M, et al. [Mineral balance during hemodialysis and hemodiafiltration]. *Minerva Urol Nefrol* 1999;51:173–6.

164. Djurhuus MS, Skott P, Hofter-Nielson O, et al. Insulin increases renal magnesium excretion: a possible cause of magnesium depletion in hyperinsulinemic states. *Diabet Med* 1995;12:664–9.

165. Hwang DL, Yen CF, Nadler JL. Insulin increases intracellular magnesium transport in human platelets. *J Clin Endocrinol Metab* 1993;76:549–53.

166. Kodama N, Nishimuta M, Suzuki K. Negative balance of calcium and magnesium under relatively low sodium intake in humans. *J Nutr Sci Vitaminol* 2003;49:201–9.

167. Sjögren A, Florin Chastre J, Nilsson P. Evaluation of magnesium status in Crohn’s disease as assessed by intracellular analysis and magnesium infusion. *Scand J Gastroenterol* 1988;23:555–61.

168. Oralewska B, Zawadzki J, Janikowska I, et al. Disorders of magnesium homeostasis in the course of liver disease in children. *Magnes Res* 1996;9:125–8.

169. Rylander R, Tallheden T, Vormann J. Acid-base conditions regulate calcium and magnesium homeostasis. *Magnes Res* 2009;22:262–5.

170. Rylander R, Remer T, Berkemeyer S, et al. Acid-base status affects renal magnesium losses in healthy, elderly persons. *J Nutr* 2006;136:2374–7.

171. Ryden E, Rude RK. Low intracellular magnesium in patients with acute pancreatitis and hypocalcemia. *West J Med* 1990;152:145–8.

172. Papazachariou IM, Martinez-Isla A, Efthimiou E, et al. Magnesium deficiency in patients with chronic pancreatitis identified by an intravenous loading test. *Clin Chim Acta* 2000;302:145–54.

173. Liannis G, Gianoutsos C, Eliaf S. Acute pancreatitis-induced hypomagnesemia. *Panreatology* 2001;1:74–6.

174. Bhathal P, Thareja S, Prakash S, et al. Micronutrient antioxidant intake in patients with chronic pancreatitis. *Trop Gastroenterol* 2004;25:69–72.

175. Markell MS, Altura BT, Sarn Y, et al. Deficiency of serum ionized magnesium in patients receiving hemodialysis or peritoneal dialysis. *Am J Kidney Dis* 1993;22:680–4.

176. Shabajee N, Lamb EJ, Stur A, et al. Magnesium deficiency in chronic inflammatory bowel disease and requirements during intravenous nutrition. *J Parenter Enteral Nutr* 1981;5:15–19.

177. Barton CH, Vaziri ND, Martin DC, et al. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. *Am J Med* 1987;83:693–9.

178. Nozue T, Kobayashi T, Kodama T, et al. Pathogenesis of cyclosporin-induced hypomagnesemia. *J Pediatr* 1992;120:638–40.

179. Millane T, Wilson AJ, Patel MK, et al. Mitochondrial calcium deposition in association with cyclosporine therapy and myocardial magnesium depletion: a serial histologic study in heart transplant recipients. *J Heart Lung Transplant* 1994;13:473–80.

180. Rob PM, Goebel Y, Lebeau A, et al. Myocardial magnesium depletion during cyclosporine treatment, associated with reciprocal calcium overload, can be prevented by plentiful dietary magnesium supply. *Clin Invest* 1994;74:127–137.

181. Roffi M, Kanaka C, Mullis PE, et al. Hypomagnesemia in children with newly diagnosed insulin-dependent diabetes mellitus. *Am J Nephrol* 1994;14:201–6.

182. Rejusová V, Polakovicová D, Steffková K, et al. [A decrease in magnesium in the serum and blood lymphocytes after intravenous infusion of glucose]. *Cas Lek Cesk* 1991;130:513–5.
200. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. *QJM* 2010;103:387–95.

201. Stendig-Lindberg G, Shapiro Y, Epstein Y, et al. Changes in serum magnesium concentration after strenuous exercise. *J Am Coll Nutr* 1987;6:35–40.

202. Spasov AA, Iezhitsa IN, Kravchenko MS, et al. Features of central neurotransmission in animals in conditions of dietary magnesium deficiency and after its correction. *Neurosci Behav Physiol* 2009;39:645–53.

203. Hanna S. Influence of large doses of vitamin D on magnesium metabolism in rats. *Metabolism* 1961;10:732–43.

204. Grobin W. A New Syndrome, Magnesium-Deficiency Tetany. *Can Med Assoc J* 1960;82:1034–5.

205. Gerst PH, Porter MR, Fishman RA. Symptomatic magnesium deficiency in surgical patients. *Ann Surg* 1964;159:402–6.

206. Allou A, Begon S, Chassaing C, et al. Does Mg2+ deficiency induce a long-term sensitization of the central nociceptive pathways? *Eur J Pharmacol* 2003;469:65–9.

207. Durlach J, Pagès N, Bac P, et al. Headache due to photosensitive magnesium depletion. *Magnes Res* 2005;18:109–22.

208. Cevette MJ, Barrs DM, Patel A, et al. Phase 2 study examining magnesium-dependent tinnitus. *Int Tinnitus J* 2011;16:168–73.

209. Agarwal R, Iezhitsa IN, Agarwal P, et al. Mechanisms of cataractogenesis in the presence of magnesium deficiency. *Magnes Trace Elem* 2011;24:65–9.

210. Mccoy JH, Kenney MA. Depressed immune response in the magnesium-deficient rat. *J Nutr* 1975;105:791–7.

211. Siwek M, Wrobel A, Dudek D, et al. [The role of copper and magnesium in the pathogenesis and treatment of affective disorders]. *Psychiatr Pol* 2005;39:911–20.

212. Cevette MJ, Vörmann J, Franz K. Magnesium and hearing. *J Am Acad Audiol* 2003;14:202–12.

213. Kitlisski MJ, Vormann J, Vörmann K. Magnesium deficiency in lymphocytes of migraine patients - effect of magnesium-rich mineral water intake. *Clin Chim Acta* 1995;245:291–5.

214. Rude RK, Oldham SB, Singer FR. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. *Clin Endocrinol* 1976;5:209–24.

215. Jeon B, Wolfswinkel JM, Schoeman JJ, et al. Epileptiform-type convulsions and magnesium deficiency. *Aviat Space Environ Med* 1979;50:734–5.

216. Spisák V. [Magnesium loading test in cardiovascular diseases]. *Vnitr Lek* 1992;38:337–44.

217. de Lordeś Lima M, Cruz T, Pousada JC, et al. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care* 1998;21:682–6.

218. Hosseini JM, Niemela JE, Elin RJ. Mononuclear blood cell magnesium in older subjects: evaluation of its use in clinical practice. *Ann Clin Biochem* 1995;32(Pt 4):435.

219. Lim P, Jacob E, Dong S, et al. Values for tissue magnesium as a guide in detecting magnesium deficiency. *J Clin Pathol* 1969;22:417–21.

220. Solarska K, Stepniewski M, Pach J. Concentration of magnesium in hair of inhabitants of down-town Krakow, the protective zone of Strop-Mill “Huta im. Sendzimira” and Tokarnia village. *Przegl Lek* 1995;52:263–6.

221. Kozielec T, Salacka A, Radomska K, et al. The influence of magnesium supplementation on magnesium and calcium concentrations in hair of children with magnesium shortage. *Magnes Res* 2001;14:33–8.

222. Durlach J, Pagès N, Bac P, et al. Importance of the ratio between ionized and total Mg in serum or plasma: new data on the regulation of Mg status and practical importance of total Mg concentration in the investigation of Mg imbalance. *Magnes Res* 2002;15:203–5.

223. Rude RK, Stephen A, Nadler J. Determination of red blood cell intracellular free magnesium by nuclear magnetic resonance as an assessment of magnesium depletion. *Magnes Trace Elem* 1991;10:117–21.

224. Markell MS, Altura BT, Barbour RL, et al. Ionized and total magnesium levels in cyclosporin-treated renal transplant recipients: relationship with cholesterol and cyclosporin levels. *Clin Sci* 1993;85:315–8.

225. Thomas J, Millot JM, Sebille S, et al. Free and total magnesium in lymphocytes of migraine patients - effect of magnesium-rich mineral water intake. *Clin Chim Acta* 2000;295:63–75.

226. Elisaf M, Panteli K, Theodorou J, et al. Fractional excretion of magnesium in normal subjects and in patients with hypomagnesaemia. *Magnes Res* 1997;10:315–20.

227. Nadler JL, Malayan S, Luong H, et al. Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. *Diabetes Care* 1992;15:835–41.

228. Toto KH, Yucha CB. Magnesium: homeostasis, imbalances, and therapeutic uses. *Crit Care Nurs Clin North Am* 1994;6:767–83.

229. Van Hook JW. Endocrine crises. Hypermagnesemia. *Crit Care Clin* 1991;7:215–23.

230. Salem M, Konsinski N, Munoz R, et al. Progressive magnesium deficiency increases mortality from endotoxin challenge: protective effects of acute magnesium replacement therapy. *Crit Care Med* 1995;23:108–18.

231. Whang R. Clinical disorders of magnesium metabolism. *Compr Ther* 1997;23:168–73.

232. Amighi J, Sabeti S, Schlager O, et al. Phase 2 study examining the role of copper and magnesium in the pathogenesis and treatment of affective disorders. *Magnes Trace Elem* 2005;28:232–37.

233. Stepniewski M, Stepniewski M, Nessler J, et al. The effect of caffeinated and decaffienated coffee on magnesium and electrolytes: the protective effect of decaffienated coffee. *Vnitr Lek* 1992;38:337–44.

234. Spisák V. [Magnesium loading test in cardiovascular diseases]. *Vnitr Lek* 1992;38:337–44.

235. de Lordeś Lima M, Cruz T, Pousada JC, et al. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care* 1998;21:682–6.

236. Hosseini JM, Niemela JE, Elin RJ. Mononuclear blood cell magnesium in older subjects: evaluation of its use in clinical practice. *Ann Clin Biochem* 1995;32(Pt 4):435.
Correction: Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis

DiNicolantonio JJ, O'Keefe JH, Wilson W. Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis. *Open Heart* 2018;5:e000668. doi: 10.1136/openhrt-2017-000668.

The following sentence in the abstract ‘Certain individuals will need to supplement with magnesium in order to prevent suboptimal magnesium deficiency, especially if trying to obtain an optimal magnesium status to prevent chronic disease.’ should be: ‘Certain individuals will need to supplement with magnesium in order to prevent subclinical magnesium deficiency, especially if trying to obtain an optimal magnesium status to prevent chronic disease.’

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

*Open Heart* 2018;5:e000668corr1. doi:10.1136/openhrt-2017-000668corr1